| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BSX | Common Stock | Gift | $0 | -2.52K | -1.13% | $0.00 | 221K | Feb 9, 2023 | Direct | |
| transaction | BSX | Common Stock | Gift | $0 | -11K | -4.98% | $0.00 | 210K | Feb 13, 2023 | Direct | |
| transaction | BSX | Common Stock | Gift | $0 | +630 | +16.96% | $0.00 | 4.34K | Feb 9, 2023 | By Child | F1 |
| holding | BSX | Common Stock | 68.1K | Feb 14, 2023 | By 401(k) | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BSX | Performance Share Units | Award | $0 | +13.9K | $0.00 | 13.9K | Feb 14, 2023 | Common Stock | 13.9K | Direct | F3, F4 | ||
| transaction | BSX | Restricted Stock Units | Award | $0 | +17.4K | $0.00 | 17.4K | Feb 14, 2023 | Common Stock | 17.4K | Direct | F5, F6 | ||
| transaction | BSX | Stock Option (Right to Buy) | Award | $0 | +45.4K | $0.00 | 45.4K | Feb 14, 2023 | Common Stock | 45.4K | $47.28 | Direct | F7 |
| Id | Content |
|---|---|
| F1 | The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose. |
| F2 | Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. |
| F3 | Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| F4 | On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. |
| F5 | Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| F6 | Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. |
| F7 | Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. |